Defining risk and personalizing treatment of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

2018-08-01T16:26:40+00:00

Genetic screening and tests of kidney size can help nephrologists identify high-risk patients for new or experimental treatments, moderate-risk patients for close surveillance, and low-risk patients for reassurance. These tests, however, are costly and not widely available. We will confirm the usefulness of these tests and make them less costly, allowing for increased use in clinics.